[低分子医薬品] Lonza Launches Early-Intermediates Supply Initiative for Small-Molecule APIs

・Is aimed at addressing concerns regarding overdependence on regional supply of pharmaceutical ingredients to the Western pharmaceutical industry
・Leverages more than 600m3 chemical capacity at the Visp (CH) chemical complex operating under ISO quality systems
・Provides a critical link in Lonza’s end-to-end service offering covering early intermediates, active pharmaceutical ingredients (APIs), drug product intermediates and specialized finished drug product supply
(リンクより全文をご覧頂けます/英語)

• リリース情報を見る
• リリース元を見る